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Introduction
There are currently no effective therapies for patients with advanced thyroid cancer, which includes patients diagnosed with advanced papillary thyroid cancer (PTC) or anaplastic thyroid cancer (ATC) (1) . Notably, ATC is one of the most aggressive human cancers with greater than 95% mortality at 6 months. Extrathyroidal invasion and metastasis are the most common causes of thyroid cancer-related death, and metastasis to the bone predicts a significantly worse prognosis (2) . Although much effort has been devoted to decipher the mechanisms involved in the progression of this cancer, little progress has been made in the development of new therapies (1, 3) .
Src family kinases (herein referred to as SFKs or Src) are a multifunctional nonreceptor tyrosine kinase family that regulates a variety of cellular processes, including growth, survival, migration, and invasion (4) . SFKs regulate these pro-tumorigenic functions via activation of downstream signaling pathways, including mitogen-activated protein kinase (MAPK/ERK), phosphatidylinostitol-OH kinase (PI3K), signal transducer and activator of transcription-3 (Stat3), p130Cas, paxillin, and focal adhesion kinase (FAK). SFKs are overexpressed and/or activated in many tumor types (5) (6) (7) (8) (9) (10) . Of the nine SFK members, c-Src, Fyn, and Yes are most widely expressed, and c-Src itself has been most frequently implicated in tumorigenesis and metastasis (11) . c-Src has been shown to play an important role in regulating osteoclast function and tumor colonization to the bone, making Src an attractive therapeutic target for the prevention and treatment of bone metastases (12, 13) . While the remaining SFK members are expressed primarily in cells of hematopoietic origin, recent studies have shown that Lyn, Fyn, and Fgr are expressed and activated in epithelial-derived cancers (14) (15) (16) (17) . (18) , and AZD0530 (saracatinib; AstraZeneca) (19) . Dasatinib is approved by the U.S. Food and Drug Administration (FDA) for patients with imatinib-resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Since inhibition of Src has the potential to inhibit the development and progression of metastases, Src inhibitors are being further investigated as anti-metastatic agents in both adjuvant and treatment settings (20, 21) .
Src signaling and the efficacy of SFK pathway inhibition has not been well studied in advanced thyroid cancer, and no studies have addressed the role of this pathway in thyroid cancer metastasis. In one previous study, FAK protein was overexpressed in a subset of PTC and ATC, but the phosphorylation status of FAK was not examined (22) . We were the first to show that FAK is phosphorylated on a well characterized Src-dependent site (Y861) in a subset of PTC patient tumor samples, and we predict these tumors will be more aggressive and/or responsive to Src-directed therapies (23) . The goals of this study were to evaluate the effects of Src inhibition using the clinically available Src inhibitor, dasatinib, on thyroid cancer growth and metastasis in vitro and in vivo.
Materials and Methods

Cell culture and generation of stable cell lines
Human thyroid cancer cell lines C643, TPC1, SW1736, BCPAP, K1, 8505C, HTh74, and HTh7 were authenticated by short tandem repeat profiling, as previously described (24). Cells were grown in RPMI (Invitrogen) containing 5%FBS (HyClone) and maintained at 37°C in 5% CO2 (24). BCPAP cells were transduced with pBABE-hygro, pBABE-WT-c-Src (Addgene plasmid 26983), or pBABE-c-Src-Dasatinib-Resistant-T338I (Addgene plasmid 26980) retrovirus, and selected with hygromycin (0.1 mg/ml) (25) .
Cellular growth assays
Cells (500/well for TPC1 and K1, 1000/well for 8505C, 1500/well for C643, and 2000/well for BCPAP, SW1736, HTh74, and HTh7) were plated in triplicate in 96-well plates, and 24 hours later, cells were treated with increasing doses of dasatinib (BMS-354825; BristolMyers Squibb), as indicated. Cell growth was analyzed using the sulforhodamine B (SRB) assay (26) . Briefly, after 72 hours of drug exposure, cells were fixed with 10% trichloroacetic acid at 4°C, and stained with 0.057% SRB (Sigma), after which unbound stain was removed by washing with 1% acetic acid. Protein-bound SRB was solubilized with 10 mmol/L unbuffered Tris base, and optical density was measured at absorbance wavelength of 570 nm.
Cell cycle analysis
Subconfluent cells were treated with vehicle (DMSO), 10, or 50nM dasatinib in RPMI containing 5% FBS for 48 hours, as previously described (23, 27) . Cell pellets were collected and stained with saponin/propidium iodide, and cell cycle distribution was determined as previously described (23, 27) .
Apoptosis assays
Cells were plated in duplicate in white-walled 96-well plates, and 24 hours later treated with vehicle (DMSO), 10 or 50 nM dasatinib for 24 hours in media supplemented with 0.1% FBS. Caspase-3/7 activities were measured using a luminescent CaspaseGlo-3/7 Assay (Promega).
Soft Agar Colony Formation
Cells (10 4 ) were suspended in 0.3% agar with complete media, and plated on a base layer of 0.64% agar (Difco Agar Noble, BD Biosciences) in 6-well dishes. Cells were treated with vehicle (DMS0), 10, or 50nM dasatinib, and media containing vehicle or drug was replenished every 3-4 days for a total of 20 days. Colonies were stained with nitroblue tetrazolium chloride (Amresco; 5 mg/mL), and incubated overnight at 37° C to develop the stain.
Colonies were counted using Image J software.
Western blotting
Cells were treated with the indicated doses of dasatinib or vehicle (DMSO) and harvested in CHAPS lysis buffer containing 10 mmol/L CHAPs, 50mmol/L Tris (pH 8.0), 150 mmol/L NaCl, and 2 mmol/L EDTA with 10 μmol/L Na 3 VO 4 and 1x protease inhibitor cocktail (Roche). Protein extracts were resolved on 8% or 10% PAGE-SDS gels and transferred to Immobilon-P membranes (Millipore), as previously described (23, 27) . Membranes were incubated at 4°C overnight with the following antibodies: pY416-SFK, SFK, Lyn, Fyn, Fgr, Yes, c-Src, pY710-Stat3, Stat3, pY410-130Cas, pY118-Paxillin, Paxillin, pS473-Akt, Akt, FAK (Cell Signaling), pY861-FAK (Invitrogen), ppERK1/2, total ERK2 (Santa Cruz), or α-tubulin (CalBiochem) diluted in 5% nonfat dry milk or 5% BSA in 20 mmol/L Tris, pH 7.4, 138 mmol/L NaCl, 0.1% Tween (TBST). Blots were incubated with secondary goat anti-rabbit or goat antimouse horseradish peroxidase-conjugated antibodies (GE Healthcare) and proteins were detected by enhanced chemiluminescence (ECL) detection (Pierce) (23, 27) .
Immunoprecipitation
Cells were lysed in RIPA buffer (10 mmol/L Tris (pH7.4), 100 mmol/L NaCl, 1 mmol/L NaF, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.1%SDS, 10% glycerol, 0.5% sodoim deoxycholate, 1% Triton X-100, 1 mmol/L PMSF, 1x protease inhibitors, 2 mmol/L Na 3 VO 4 ). Equal amounts of protein 10% PAGE-SDS gels, and detected using the ImmunoCruz IP/WB optima F system (Santa Cruz) with the indicated primary antibodies and ECL as described above.
Orthotopic murine model
BCPAP and 8505C cells (5 x 10 5 ) engineered to express a luciferase-IRES-GFP plasmid were injected into the right thyroid lobe of nude mice, as previously described (28) (29) (30) . Briefly, 
Experimental Metastasis Model
Male athymic nude mice (Harlan; 25 grams; 5 weeks old) received D-luciferin (3 mg) via IP injection, and five minutes later each mouse was anesthetized using isofluorane. BCPAPluc-IRES-GFP cells (10 5 cells in 100 ul PBS) were injected into the left ventricle of nude mice using a 25-gauge needle, as previously described (31) . Successful left ventricle injection was monitored by the pulsatile flow of red blood into the needle hub indicating correct placement, and by whole body bioluminescence immediately following injection. Metastatic progression was monitored weekly by IVIS imaging. Mice were sacrificed if they lost > 20% body weight, and based on moribund criteria. All animal studies were performed in accordance with the animal protocol procedures approved by the Institutional Animal Care and Use Committee at the University of Colorado Denver.
Drug preparation and administration
For in vivo studies, dasatinib (50 mg/kg) was prepared for daily oral gavage (5 days/week) in 80 mM sodium citrate buffer, pH 3.0. For the orthotopic murine model, mice were randomized on day 10 based on bioluminescence activity to receive drug or vehicle. In the metastatic murine model, mice received dasatinib or vehicle, as described above, starting 2 days before intracardiac injection (pre-treatment), or on day 11 following randomization (posttreatment).
Results
Effects of dasatinib on thyroid cancer cell growth, apoptosis, and transformation.
To study the role of SFK signaling in thyroid cancer, a panel of 8 thyroid cancer cell lines representing distinct thyroid tumor types (papillary thyroid cancer, PTC and anaplastic thyroid cancer, ATC), and clinically relevant oncogenic mutations (BRAF, RAS, RET/PTC1, PIK3CA) (Table 1 and (24)) was used to study sensitivity to dasatinib (32) . Figure 1A shows that treatment with increasing doses of dasatinib (0.019 to 1.25 μM) for 3 days inhibited the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by ~50% at low nanomolar concentrations, while higher concentrations were required to inhibit the growth of the K1 cell line. In contrast, the 8505C, HTh7, and HTh74 cell lines were not inhibited > 50% by dasatinib treatment, even at doses > 1 μM (Fig. 1A) . IC50 values were calculated (Table 1) were resistant to dasatinib with IC50 values > 1.6 μM ( Table 1 ). The 100 nM "sensitive" demarcation was chosen based on previous studies demonstrating decreased selectivity of dasatinib at doses > 100 nM (32, 33) . Overall, we observed similar sensitivity to inhibition of Src with dasatinib and saracatinib in our previous study (23) , indicating an important role for SFKs in thyroid cancer cell growth.
To examine the mechanisms of inhibition of cell growth, cell cycle progression was evaluated in representative dasatinib-sensitive and dasatinib-intermediate cell lines (BCPAP, SW1736, K1), as well as dasatinib-resistant cell lines (8505C, HTh7, HTh74). Table 2 shows that treatment with 10 nM or 50 nM dasatinib resulted in a ~9-22% increase of cells in the G1 population in the BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in S phase. In contrast, dasatinib treatment of the resistant 8505C, HTh7, and HTh74 cell lines resulted in a 0-10% increase in cells in the G1 population (Table 2) , consistent with the resistant nature of these cells (Fig. 1A) . To further explore the mechanism of growth inhibition by dasatinib, induction of apoptosis was also tested. Figure 1B Figure 2B shows that inhibition of Src with dasatinib does not inhibit MAP kinase (ppERK1/2) at low doses (1 or 10 nM), consistent with our previous studies using saracatinib (23) . However, partial, but variable inhibition of ppERK1/2 was observed at higher doses of dasatinib (50 nM We also evaluated the effects of SFK inhibition on the phosphorylation of Stat3 and pAkt signaling, which have been associated with resistance to Src inhibitors, and promote survival in other tumor models (37) (38) (39) (40) . Figure 2B shows that pStat3 was not detected in the PTC-derived BCPAP and K1 cell lines, while elevated levels were detected in the ATC-derived SW1736 and 8505C cells. Interestingly, no significant effects of dasatinib were observed on pStat3 levels. cancer cells, which has not been previously characterized. Figure 3A shows that c-Src and Lyn are the only family members expressed, while Fyn, Yes, Lck, and Fgr were not detected. To determine whether c-Src and Lyn are activated in thyroid cancer cells, extracts were prepared from cells treated with or without dasatinib, and c-Src or Lyn were immunoprecipitated using anti-c-Src or anti-Lyn specific antibodies, followed by Western blotting to detect activation of cSrc and Lyn using the pY416Src antibody, which cross-reacts with the activated and autophosphorylated form of c-Src (pY416) and Lyn (pY397). Figure 3B (top) shows that equivalent levels of total c-Src are immunoprecipitated in BCPAP cells treated with or without dasatinib. Activated pY416Src is specifically detected in the c-Src immunoprecipitates, and pY416Src is inhibited by dasatinib treatment (Fig. 3B top) . Lyn was also efficiently immunopreciptated, but phosphorylation of Lyn was not detected in the Lyn immunoprecipitations (Fig. 3B) . Similar results were observed in the 8505C cells (Fig. 3B,   bottom) . Taken together, these data indicate that c-Src is the predominant SFK activated in representative sensitive (BCPAP) and resistant (8505C) thyroid cancer cells.
In addition to its role as a potent SFK inhibitor, dasatinib is a multikinase inhibitor (32) .
To test the specific role of c-Src in response to dasatinib treatment, we tested the ability of a cSrc inhibitor-resistant transgene to rescue the effects of dasatinib on signaling and cell growth.
For these studies we took advantage of the gatekeeper residue of Src (T338), which is required for dasatinib binding, to test whether expression of this dasatinib-resistant mutant rescues cells from dasatinib treatment (25, 42, 43) . The c-Src dasatinib-resistant mutant (T338I, herein referred to as Src-RES), wild-type Src (Src-WT), or empty vector (pBABE-hygro) were stably expressed in the Src inhibitor-sensitive BCPAP cells at near physiologic levels (~1.5-fold above endogenous c-Src (Fig. 3C and data not shown) . As expected, dasatinib treatment inhibits pY416SFK and pY861FAK in cells expressing empty vector (pBABE-hygro) or Src-WT (Fig.   3C ). In cells expressing Src-RES, pY416SFK levels were not inhibited by dasatinib treatment, indicating that the gatekeeper residue, Thr 338, is necessary for inhibition of Src by dasatinib.
Similarly, inhibition of pY861FAK by dasatinib was also blocked in cells expressing the Src-RES mutant, consistent with this residue being a major phosphorylation site targeted by Src (Fig.   3C ).
We next tested the c-Src-dependent effects of dasatinib on growth of the BCPAP cells (Fig. 3D) . As expected, we observed a dose dependent decrease of growth in Src-WT expressing cells, with an IC50 of 42 nM, consistent with the response of parental (nontransduced) and empty vector transduced cells (40 nM; Table 1 ). Notably, expression of the Src-RES gatekeeper mutant blocked the growth inhibitory effects of dasatinib, shifting the IC50 to 1200 nM (Fig. 3D) . Similar results were observed in the SW1736 cells (data not shown). Thus, these data provide strong evidence that c-Src is the primary mediator of cell growth in response to Src inhibitor treatment in thyroid cancer cells.
Inhibition of Src with dasatinib inhibits PTC growth in a preclinical orthotopic mouse model.
We next evaluated the in vivo antitumor effects of Src inhibition in an orthotopic thyroid cancer model using the BCPAP cells (sensitive to dasatinib in vitro) and 8505C cells (resistant to dasatinib in vitro). BCPAP or 8505C cells stably expressing a luciferase-IRES-GFP plasmid were injected into the right thyroid gland of athymic nude mice, and tumor establishment and progression were monitored by measuring luciferase activity using the Intravital Imaging System (IVIS). Daily treatment with dasatinib (50 mg/kg) was initiated on day 10. Using this approach, a significant inhibition of BCPAP orthotopic tumor growth was observed 6 days post-treatment (day 16, p=0.014), which was sustained through days 23 and 29 (p= 0.0003), compared to vehicle-treated mice (Fig. 4A, left) . Representative bioluminescence images of orthotopic tumors are shown in Figure 4B Fig. 4C left) . Strikingly, three out of eight dasatinibtreated BCPAP orthotopic mice did not have measurable tumor after therapy. In contrast, the growth of 8505C-derived tumors was not significantly inhibited by dasatinib treatment at any time point, as measured by bioluminescence imaging (Fig. 4A, right) , and final tumor volumes (p=0.8; Fig. 4C, right) . Thus, these data validate our in vitro findings and show that inhibition of Src with dasatinib strongly inhibits thyroid tumor growth in vivo.
Inhibition of Src with dasatinib blocks PTC metastasis.
One of the most lethal characteristics of thyroid cancer is the metastatic spread to distant sites, especially to the bone. The orthotopic model has resulted in limited distant metastases, and to date, there have been no bone metastasis models in thyroid cancer. We have therefore established an experimental metastasis model using an intracardiac injection approach which allows for the widespread dissemination of tumor cells. Using this model system, we tested the Src inhibitor-sensitive BCPAP (PTC) cells, which have formed consistent distant metastases with a 70-90% take rate. For these studies, BCPAP-luc-IRES-GFP cells were injected into the left ventricle of athymic nude mice. Successful left ventricle injection was monitored by the spontaneous entrance of pulsatile blood into the hub of the syringe, and by bioluminescence imaging immediately after injection to visualize the widespread distribution of luciferase expressing tumor cells (Fig. 5A) . Representative histologic images of bone metastases are shown in Fig. S1 .
To determine the role of Src in metastasis, we first utilized an adjuvant treatment approach, in which mice were given vehicle or dasatinib (50 mg/kg) by daily oral gavage 48 hours before intracardiac injection of cancer cells. Using this approach, we observed a ~70% take rate in the vehicle-treated mice, compared to the pretreatment group where none of the mice developed distinct metastatic tumors, even after 6 weeks (Fig. 5C ). Representative Figure 5D shows that dasatinib-treated mice had a significantly increased overall survival when compared to vehicle treated mice, with a mean survival of 63 days for the vehicle-treated mice versus 123 days for the dasatinib-treated mice ( Fig. 5D ; p = 0.0015). Next, to determine the effects of dasatinib treatment on established metastases, these studies were repeated and mice were treated with dasatinib (50 mg/kg) after the establishment of metastases on day 11 (Fig. S2A) . Figure S2C shows that dasatinib treatment resulted in a sustained inhibition of metastatic tumor growth starting ~10 days after treatment (2-way ANOVA; p = 0.004). Representative images, showing inhibition of metastasis at week 7, are shown (Fig. S2B) . Overall, these results provide the first demonstration for Src signaling in thyroid cancer metastasis, and indicate that inhibition of Src with dasatinib represents a promising therapeutic strategy to block both primary and metastatic tumor growth in thyroid cancer patients.
Discussion
Little is known about the role of Src and FAK and the efficacy of SFK inhibitors in thyroid cancer. Our group was the first to demonstrate that elevated levels of phospho-SFK and FAK are present in thyroid cancer cell lines, and that phospho-FAK is present in a subset of PTC tumor samples (23) . We further showed that inhibition of Src with the more selective Src inhibitor, saracatinib, inhibits the growth and invasion of thyroid cancer cell lines expressing elevated levels of phospho-FAK (23). In the current study, we have further tested the role of SFK signaling in thyroid cancer using dasatinib, which is a potent ATP-competitive inhibitor of Src, which is FDA-approved for the treatment of patients with leukemia, and is being tested in In this study, we identified cells with high, moderate, and low sensitivity to dasatinib in vitro, and found that treatment with dasatinib blocks SFK and FAK signaling. Interestingly, we did not find a clear correlation between basal levels of these signaling molecules, or inhibition of these molecules by dasatinib with sensitivity to dasatinib, although phospho-FAK levels may be higher in the sensitive cell lines (Fig. 2A) . The lack of correlation between phospho-SFK levels and sensitivity to dasatinib is similar to our previous studies using the Src inhibitor, saracatinib, as well studies in other tumor types, and suggest that even low levels of SFK activity are sufficient for these biological responses (23, 44, 45) . We also evaluated Stat3 and Akt signaling, which have been shown to promote survival and mediate resistance to Src inhibitor treatment in other tumor types (37) (38) (39) (40) . Importantly, we did not observe regulation of pStat3 in response to dasatinib treatment, and although pAkt was inhibited with higher concentrations of dasatinib in the BRAF/PIK3CA-mutant K1 cells, low to undetectable levels of pStat3 and pAkt were observed in both sensitive and resistant cell lines, indicating that these pro-survival pathways are likely not major targets of Src signaling in thyroid cancer. Finally, we found that dasatinib treatment inhibited ppERK1/2 at higher concentrations, but that this inhibition was variable, suggesting that the MAP kinase pathway is not a major target of Src in thyroid cancer cells. Accordingly, we did not identify any correlation between known oncogene mutations (BRAF, RAS, PIK3CA, RET/PTC1) and sensitivity to dasatinib (Table 1) , consistent with our previous studies with the more selective Src inhibitor, saracatinib (23) , as well as other tumor types (33, 40) . Thus, additional studies are needed to identify predictive biomarkers of response to determine which patients will benefit the most from Src-directed therapies. Although dasatinib is a multi-kinase inhibitor, in addition to a potent inhibitor of Src, our data show a strong correlation between the sensitivity of thyroid cancer cells to dasatinib (Fig. 1) and the more selective Src inhibitor, saracatinib (23) , indicating an important role for Src in thyroid cancer cell growth, similar to one previous study in thyroid cancer (46) . We have further shown the inhibitory effects of dasatinib are accompanied by inhibition of the Src pathway at low nanomolar concentrations ( Fig. 2A) , indicating these effects are likely mediated by Src and FAK signaling. To identify the specific SFK important in thyroid cancer, we characterized the expression of six SFK members in thyroid cancer cells, and show that c-Src and Lyn are the predominant members expressed (Fig. 3A) . Interestingly, we found that while both c-Src and Lyn are expressed, c-Src is the predominant SFK phosphorylated (Fig. 3B) . Since dasatinib can inhibit all Src family kinase members, as well as other kinases, we further tested the role of c-Src in the response to dasatinib using a gatekeeper approach. These studies showed expression of the c-Src gatekeeper mutant (Src-RES) rescues dasatinib-mediated inhibition of thyroid cancer cell growth, as well as inhibition of Src signaling, providing strong evidence that c-Src is the primary mediator of growth in response to dasatinib treatment (Fig. 3D ). While these results do not prove Lyn has no effect, these data strongly support c-Src as the dominant if not only mediator of growth in response to Src inhibitors in thyroid cancer cells. These results are in contrast to recent studies in prostate and breast cancer, where both c-Src and Lyn are expressed and activated, and shown to mediate distinct biologic responses (15, 16, 47) .
A number of studies in other tumor types, including colon cancer and NSCLC have shown that Src primarily regulates invasion and metastasis (33, 48, 49) . Our studies show that treatment with dasatinib not only blocks transformation and metastatic progression, but also inhibits thyroid cancer cell growth. These results indicate that the use of Src inhibitors may have higher therapeutic efficacy in thyroid cancer, due to the potential to inhibit primary tumor growth (Fig. 4) , in addition to metastatic outgrowth ( Fig. 5; Fig. S2 ). 
Distant metastasis to the bone represents one of the most lethal characteristics of thyroid cancer, and there are currently no effective therapeutic options for these patients. Due to the role of Src signaling in bone metastases in other tumor types, and the importance of distant metastases in thyroid cancer, we developed an experimental metastasis model using an intracardiac injection approach. This is the first report describing the establishment of a thyroid cancer metastasis model to bone. Using a pre-treatment, adjuvant approach, we found that while ~70% of mice developed metastases in the vehicle-treated control group, no mice developed metastases in the dasatinib-pretreated group after 6 weeks of treatment (Fig. 5) . We found that although these mice exhibited a significantly longer survival of ~60 days compared to vehicle-treated mice, even after discontinuation of dasatinib (Fig. 5D) , the majority of these mice developed tumors. To determine if inhibition of Src could block the progression of established metastases, we used a post-treatment approach, where mice were treated with dasatinib after metastatic tumor establishment (Fig. S2) . Using this approach, dasatinib treatment significantly inhibited metastatic tumor progression by ~10-fold (Fig. S2) . Taken together, these results indicate that Src activity is important for tumor cell growth and/or survival, rather than early metastatic cell seeding. These results are consistent with our in vitro growth data (Fig. 1) , as well as previous studies in prostate and breast cancer (16, 25) . Thus, the precise role of Src in the progression of latent metastases, which is an important clinical problem in thyroid cancer (50) , will be of particular interest to test in future studies. Collectively, these studies indicate that Src inhibitors will likely need to be used long-term or in combination with other therapies in order to achieve complete tumor remission, but nonetheless, these data provide a strong rationale for Src inhibitors as anti-tumor and anti-metastatic agents in patients with advanced, metastatic disease.
In conclusion, our results show that inhibition of Src with dasatinib inhibits thyroid cancer cell growth and transformation in vitro and tumor growth and metastatic ougrowth in vivo. We 
